Clinical trial
Combination Chemotherapy, Radiation Therapy, and RSR13 in Treating Patients With…
NCT00004202 · Spectrum Pharmaceuticals, Inc, Industry · Completed
Key facts
| NCT number | NCT00004202 |
|---|---|
| Title | Combination Chemotherapy, Radiation Therapy, and RSR13 in Treating Patients With Stage III Non-small Cell Lung Cancer |
| Official title | A Phase II Study of Induction Chemotherapy With Paclitaxel and Carboplatin Followed by Radiation Therapy With RSR13 for Locally Advanced Inoperable Non-Small Cell Lung Cancer |
| Lead sponsor | Spectrum Pharmaceuticals, Inc, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug, Radiation |
| Interventions | carboplatin, chemotherapy, efaproxiral, paclitaxel, radiation therapy |
| Start date | Oct 1, 1998 |
| Primary completion | Jan 1, 2003 |
| Completion | Jan 1, 2003 |
| First posted | Jun 25, 2004 |
| Last update posted | Aug 26, 2021 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: